Whole–genome characterization of chemoresistant ovarian cancer

C. eleganswhole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency

(2014) Bettina Meier et al.   GENOME RESEARCH

Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling

(2014) Katia Nones et al.   INTERNATIONAL JOURNAL OF CANCER

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

CDKN2D-WDFY2 Is a Cancer-Specific Fusion Gene Recurrent in High-Grade Serous Ovarian Carcinoma

(2014) Kalpana Kannan et al.   PLoS Genetics

Review of processing and analysis methods for DNA methylation array data

(2013) C S Wilhelm-Benartzi et al.   BRITISH JOURNAL OF CANCER

Punctuated Evolution of Prostate Cancer Genomes

(2013) Sylvan C. Baca et al.   CELL

Criteria for Inference of Chromothripsis in Cancer Genomes

(2013) Jan O. Korbel et al.   CELL

Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations

(2013) J. George et al.   CLINICAL CANCER RESEARCH

P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives

(2013) Ziyad Binkhathlan et al.   CURRENT CANCER DRUG TARGETS

Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently?

(2013) Michael L. Friedlander et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling

(2013) Ali Bashashati et al.   JOURNAL OF PATHOLOGY

Landscape of genomic alterations in cervical carcinomas

(2013) Akinyemi I. Ojesina et al.   NATURE

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

Somatic Point Mutation Calling in Low Cellularity Tumors

(2013) Karin S. Kassahn et al.   PLoS One

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

RNA-SeQC: RNA-seq metrics for quality control and process optimization

(2012) David S. DeLuca et al.   BIOINFORMATICS

LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

(2012) Prue A. Cowin et al.   CANCER RESEARCH

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

(2012) T. Popova et al.   CANCER RESEARCH

Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies

(2012) S. Murray et al.   CANCER TREATMENT REVIEWS

Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations

(2012) Tobias Rausch et al.   CELL

Mutational Processes Molding the Genomes of 21 Breast Cancers

(2012) Serena Nik-Zainal et al.   CELL

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing

(2012) D. C. Koboldt et al.   GENOME RESEARCH

Combinatorics of the Breakage-Fusion-Bridge Mechanism

(2012) Marcus Kinsella et al.   JOURNAL OF COMPUTATIONAL BIOLOGY

Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease

(2012) Mauro Castellarin et al.   JOURNAL OF PATHOLOGY

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

qpure: A Tool to Estimate Tumor Cellularity from Genome-Wide Single-Nucleotide Polymorphism Profiles

(2012) Sarah Song et al.   PLoS One

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

(2011) Bo Li et al.   BMC BIOINFORMATICS

Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development

(2011) Philip J. Stephens et al.   CELL

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

(2011) Barbara Norquist et al.   JOURNAL OF CLINICAL ONCOLOGY

Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma

(2011) Robert A Soslow et al.   MODERN PATHOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Integrative genomics viewer

(2011) James T Robinson et al.   NATURE BIOTECHNOLOGY

ESRRA-C11orf20 Is a Recurrent Gene Fusion in Serous Ovarian Carcinoma

(2011) Julia Salzman et al.   PLOS BIOLOGY

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

(2011) Craig H Mermel et al.   GENOME BIOLOGY

Ovarian Cancer Development and Metastasis

(2010) Ernst Lengyel   AMERICAN JOURNAL OF PATHOLOGY

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

(2010) A. Mukhopadhyay et al.   CLINICAL CANCER RESEARCH

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

IntOGen: integration and data mining of multidimensional oncogenomic data

(2010) Gunes Gundem et al.   NATURE METHODS

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

(2010) Ignace Vergote et al.   NEW ENGLAND JOURNAL OF MEDICINE

MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery

(2010) Kai Wang et al.   NUCLEIC ACIDS RESEARCH

Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads

(2009) K. Ye et al.   BIOINFORMATICS

The Sequence Alignment/Map format and SAMtools

(2009) H. Li et al.   BIOINFORMATICS

Fast and accurate short read alignment with Burrows-Wheeler transform

(2009) H. Li et al.   BIOINFORMATICS

Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

(2009) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays

(2009) Tatiana Popova et al.   GENOME BIOLOGY

Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

(2008) E. M. Swisher et al.   CANCER RESEARCH

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

(2008) R. W. Tothill et al.   CLINICAL CANCER RESEARCH

Phase III Study of Valspodar (PSC 833) Combined With Paclitaxel and Carboplatin Compared With Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer

(2008) Catherine Lhommé et al.   JOURNAL OF CLINICAL ONCOLOGY

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

(2008) Blaise Clarke et al.   MODERN PATHOLOGY

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE